Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Cost-Effectiveness Research Resource Center

Featured

News
The Impact of Lower Cost Alternatives or Biosimilars on The Cost of Key Cancer Drugs
10/28/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and...
10/28/2023
Journal of Clinical Pathways
News
How Well Does the Enhancing Oncology Model Capture Treatment Costs in Disease Groups?
10/27/2023

Emry Lloyd

Emry Lloyd
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and...
10/27/2023
Journal of Clinical Pathways
News
The Impact of Dosing Approaches for Lenalidomide on Total Cost of Care
10/27/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US...
10/27/2023
Journal of Clinical Pathways
News
Shift to Oral Anti-Cancer Drugs Impacting OCM: Study Shows Rise in Part D Drug Expenses
10/26/2023

Brandon Twyford

Brandon Twyford
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact...
10/26/2023
Journal of Clinical Pathways
The role of cost in pathways panel discussion at CPC & CBEx 2023.
News
The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs
10/12/2023

Brandon Twyford

Brandon Twyford
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC...
10/12/2023
Journal of Clinical Pathways
Research Reports
Bone-Modifying Agent Utilization: An Analysis in Patients With Metastatic Cancer and Bone Involvement at an NCI-Designated Cancer Center
04/12/2023
Poorni M. Manohar, MD
Kyle E. Bastys
Micah Tratt
Julie Gralow, MD, FACP, FASCO
Keith D. Eaton, MD, PhD
Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.
Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.
Manohar et al investigate the...
04/12/2023
Journal of Clinical Pathways
Manish Kohli
Videos
Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
News
Study Explores the Cost-Effectiveness of Ultra-Hypofractionated Whole Breast Radiation Therapy vs Endocrine Therapy Alone vs Combination Therapy
02/14/2023

Yvette C Terrie

Yvette C Terrie
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction...
02/14/2023
Journal of Clinical Pathways
Editor's Page
The Next 5 Years for Medication Spending
02/06/2023
Winston Wong, PharmD, Editor-in-Chief
Editor-in-Chief, Winston Wong, PharmD, outlines the Global Use of Medicines 2023 report on the next 5 years of medical spending and how the health care industry must continue to improve efficiency and quality, informed by evidence-based...
Editor-in-Chief, Winston Wong, PharmD, outlines the Global Use of Medicines 2023 report on the next 5 years of medical spending and how the health care industry must continue to improve efficiency and quality, informed by evidence-based...
Editor-in-Chief, Winston Wong,...
02/06/2023
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Durvalumab Plus Gemcitabine and Cisplatin for Patients With Advanced Biliary Tract Cancer
01/30/2023

Grace Taylor

Grace Taylor
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at...
01/30/2023
Journal of Clinical Pathways
Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways

Advertisement

News

News
The Impact of Lower Cost Alternatives or Biosimilars on The Cost of Key Cancer Drugs
10/28/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and...
10/28/2023
Journal of Clinical Pathways
News
How Well Does the Enhancing Oncology Model Capture Treatment Costs in Disease Groups?
10/27/2023

Emry Lloyd

Emry Lloyd
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and...
10/27/2023
Journal of Clinical Pathways
News
The Impact of Dosing Approaches for Lenalidomide on Total Cost of Care
10/27/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US...
10/27/2023
Journal of Clinical Pathways
News
Shift to Oral Anti-Cancer Drugs Impacting OCM: Study Shows Rise in Part D Drug Expenses
10/26/2023

Brandon Twyford

Brandon Twyford
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact...
10/26/2023
Journal of Clinical Pathways
The role of cost in pathways panel discussion at CPC & CBEx 2023.
News
The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs
10/12/2023

Brandon Twyford

Brandon Twyford
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC...
10/12/2023
Journal of Clinical Pathways
News
Study Explores the Cost-Effectiveness of Ultra-Hypofractionated Whole Breast Radiation Therapy vs Endocrine Therapy Alone vs Combination Therapy
02/14/2023

Yvette C Terrie

Yvette C Terrie
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction...
02/14/2023
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Durvalumab Plus Gemcitabine and Cisplatin for Patients With Advanced Biliary Tract Cancer
01/30/2023

Grace Taylor

Grace Taylor
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at...
01/30/2023
Journal of Clinical Pathways
Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness Analyses of Ibrutinib vs Acalabrutinib vs Zanubrutinib as First-line Treatment in Patients With Chronic Lymphocytic Leukemia
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Primary Prophylaxis With G-CSF Biosimilars in Patients at Risk of Febrile Neutropenia
06/12/2022

Ellen Kurek

Ellen Kurek
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to...
06/12/2022
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
04/11/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
04/11/2024
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Grace Taylor, MS, MA
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology

Videos

Manish Kohli
Videos
Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
Jan Bewersdorf, MD
Videos
Cost-Effectiveness of Liposomal vs Conventional Cytarabine-Daunorubicin for AML
01/10/2022
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses...
01/10/2022
Journal of Clinical Pathways
Prapti Patel, MD
Videos
Real-World Efficacy, Safety of First-Line Venetoclax-Based Combination Therapy for AML
01/06/2022
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses...
01/06/2022
Journal of Clinical Pathways
Muhamad Alhaj Moustafa, MD
Videos
Real-World Utilization and Cost-Effectiveness of Yttrium-90 Ibritumomab Tiuxetan vs Bendamustine Plus Rituximab for FL and MZL
12/16/2021
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD,...
12/16/2021
Journal of Clinical Pathways
Kishan Patel, MD, Yale School of Medicine
Videos
Atezolizumab Plus Bevacizumab Unlikely Cost-Effective for Advanced HCC
07/01/2021
Kishan Patel, MD, discusses results from a study evaluating the cost-effectiveness of atezolizumab plus bevacizumab for advanced HCC, concluding that it may be too costly under current pricing.
Kishan Patel, MD, discusses results from a study evaluating the cost-effectiveness of atezolizumab plus bevacizumab for advanced HCC, concluding that it may be too costly under current pricing.
Kishan Patel, MD, discusses...
07/01/2021
Journal of Clinical Pathways
Videos
Cost-Effectiveness of Adjunctive Osimertinib for EGFR-Positive NSCLC
06/10/2021
Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.
Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.
Briana Choi, PharmD, discusses...
06/10/2021
Journal of Clinical Pathways
David Barrington, MD
Videos
Cost-Effectiveness of Lenvatinib Plus Pembrolizumab for Endometrial Cancer
06/10/2021
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
David Barrington, MD, discusses...
06/10/2021
Journal of Clinical Pathways
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
02/17/2021
02/17/2021
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 2)
05/20/2024
Michael Kolodziej, MD
John Hennessy, MBA
In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...
In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...
In part two of this two-part...
05/20/2024
Cancer Care Business Exchange
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Robert Stillman, MA, RN
Videos
Best Practices in Care Team Communication Technology: Updates From NCCN 2024
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement